Rare and Orphan Diseases

1-16 of 50

Shared Decision-Making in Squamous Cell Carcinoma of the Anal Canal
Shared Decision-Making in Squamous Cell Carcinoma of the Anal Canal
Project Oncology®
Shared Decision-Making in Squamous Cell Carcinoma of the Anal Canal
- Brian P. McDonough, MD, FAAFP
- Richard Kim, MD
Retifanlimab Across POD1UM-303 Subgroups in Squamous Cell Carcinoma of the Anal Canal
Retifanlimab Across POD1UM-303 Subgroups in Squamous Cell Carcinoma of the Anal Canal
Project Oncology®
Retifanlimab Across POD1UM-303 Subgroups in Squamous Cell Carcinoma of the Anal Canal
- Charles Turck, PharmD, BCPS, BCCCP
- Marwan G. Fakih, MD
Updates in AML Care: Evolving ASH Guidelines for Older Adults
Updates in AML Care: Evolving ASH Guidelines for Older Adults
On the Frontlines of AML/ALL
Updates in AML Care: Evolving ASH Guidelines for Older Adults
- Shelina Ramnarine, PhD
- Mikkael A. Sekeres, MD, MS
Venetoclax and Palbociclib in AML: Exploring New Findings
Venetoclax and Palbociclib in AML: Exploring New Findings
On the Frontlines of AML/ALL
Venetoclax and Palbociclib in AML: Exploring New Findings
- Ryan Quigley
- Jeffrey Tyner, PhD
- Melissa Stewart, PhD
Expanding Access to CAR T-Cell Therapy in R/R Myeloma Care
Expanding Access to CAR T-Cell Therapy in R/R Myeloma Care
Project Oncology®
Expanding Access to CAR T-Cell Therapy in R/R Myeloma Care
- Brian P. McDonough, MD, FAAFP
- Tara Graff, DO, MS
- Surbhi Sidana, MD
Optimizing Care for Older Adults With FLT3-Mutated AML
Optimizing Care for Older Adults With FLT3-Mutated AML
Global Oncology Academy
Optimizing Care for Older Adults With FLT3-Mutated AML
- Ryan Quigley
- Nicholas Short, MD
How the 2025 IMWG Guidelines are Reshaping Sequencing in R/R Multiple Myeloma
How the 2025 IMWG Guidelines are Reshaping Sequencing in R/R Multiple Myeloma
Project Oncology®
How the 2025 IMWG Guidelines are Reshaping Sequencing in R/R Multiple Myeloma
- Jennifer Caudle, DO, FACOFP
- Mansi R. Shah, MD
Surgical Insights on Gastroesophageal Cancer: Balancing Surveillance and Intervention
Surgical Insights on Gastroesophageal Cancer: Balancing Surveillance and Intervention
Project Oncology®
Surgical Insights on Gastroesophageal Cancer: Balancing Surveillance and Intervention
- Daniela Molena, MD
Optimizing Monitoring after Ide-cel in RRMM: What the Evidence Shows
Optimizing Monitoring after Ide-cel in RRMM: What the Evidence Shows
AudioAbstracts
Optimizing Monitoring after Ide-cel in RRMM: What the Evidence Shows
- Marlene Mimi Maeusli, PhD.
Tracking Lineage Infidelity in Pediatric B-ALL: New Insights From ASH
Tracking Lineage Infidelity in Pediatric B-ALL: New Insights From ASH
Project Oncology®
Tracking Lineage Infidelity in Pediatric B-ALL: New Insights From ASH
- Ryan Quigley
- Kathrin M. Bernt, MD
- Rushabh Mehta, BS
- Fatemeh Alikarami
CLL17 Trial Insights: Fixed-Duration vs Continuous Therapy in Frontline CLL
CLL17 Trial Insights: Fixed-Duration vs Continuous Therapy in Frontline CLL
Project Oncology®
CLL17 Trial Insights: Fixed-Duration vs Continuous Therapy in Frontline CLL
- Ryan Quigley
Evaluating a Lower-Intensity Treatment Regimen in AML: Phase 2 Results from PARADIGM
Evaluating a Lower-Intensity Treatment Regimen in AML: Phase 2 Results from PARADIGM
Project Oncology®
Evaluating a Lower-Intensity Treatment Regimen in AML: Phase 2 Results from PARADIGM
- Ryan Quigley
Managing MCL After BTKi Failure: The Expanding Role of CAR T-Cell Therapy
Managing MCL After BTKi Failure: The Expanding Role of CAR T-Cell Therapy
Project Oncology®
Managing MCL After BTKi Failure: The Expanding Role of CAR T-Cell Therapy
- Charles Turck, PharmD, BCPS, BCCCP
- Luhua (Michael) Wang, MD
Chronic Graft-Versus-Host Disease Care: Evolving Therapeutic Strategies
Chronic Graft-Versus-Host Disease Care: Evolving Therapeutic Strategies
Project Oncology®
Chronic Graft-Versus-Host Disease Care: Evolving Therapeutic Strategies
- Brian P. McDonough, MD, FAAFP
- Doris M. Ponce, MD, MS
Evaluating Axatilimab in Chronic GVHD: How Prior Therapies Impact Outcomes
Evaluating Axatilimab in Chronic GVHD: How Prior Therapies Impact Outcomes
Project Oncology®
Evaluating Axatilimab in Chronic GVHD: How Prior Therapies Impact Outcomes
- Hallie Blevins, PhD
Crizanlizumab’s Role in Reducing Vaso-Occlusive Crises and Opioid Use in SCD
Crizanlizumab’s Role in Reducing Vaso-Occlusive Crises and Opioid Use in SCD
Project Oncology®
Crizanlizumab’s Role in Reducing Vaso-Occlusive Crises and Opioid Use in SCD